Drug, across the briefings
Tucatinib across 12 cancers
Tucatinib appears in 12 of the briefings; its FDA label names 2 of those diseases.
| Disease | FDA label | Open Targets stage, on which gene | Trials | Active |
|---|---|---|---|---|
| Breast cancer | label names disease | approved on ERBB2 | 46 | 30 |
| Colorectal cancer | label names disease | approved on ERBB2 | 12 | 8 |
| Bladder cancer | approved on ERBB2 | — | — | |
| Cervical cancer | approved on ERBB2 | 2 | 2 | |
| Cholangiocarcinoma | approved on ERBB2 | 1 | 1 | |
| Endometrial cancer | approved on ERBB2 | — | — | |
| Esophageal cancer | approved on ERBB2 | 3 | 2 | |
| Gallbladder cancer | approved on ERBB2 | 1 | 1 | |
| Gastric cancer | approved on ERBB2 | 9 | 6 | |
| Lung cancer | approved on ERBB2 | 5 | 3 | |
| Osteosarcoma | approved on ERBB2 | — | — | |
| Small intestine cancer | approved on ERBB2 | — | — |
The label column is the briefing's openFDA stage: a label whose Indications and Usage names the disease. The Open Targets column is the furthest clinical stage recorded for the drug against any gene on that briefing's target list, in any indication. Trials are ClinicalTrials.gov interventional studies naming the drug and the disease, from the briefing's trials stage; a dash means the briefing did not search this drug in that disease (it searches the drugs Open Targets lists against its own genes), which is not the same as none. Salt forms, biosimilar suffixes and formulation words are merged by the same rule the briefings use.